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Abstract
Breast cancer (BC) is the most prevalent type worldwide, besides being one of the most common causes of death
among women. It has been suggested that sporadic BC is most likely caused by low-penetrance genes, including
those involved in DNA repair mechanisms. Furthermore, the accumulation of DNA damage may contribute to breast
carcinogenesis. In the present study, the relationship between two DNA repair genes, viz., XRCC1 (Arg399Gln) and
XRCC3 (Thr241Met) polymorphisms, and the levels of chromosome damage detected in 65 untreated BC women
and 85 healthy controls, was investigated. Chromosome damage was evaluated through micronucleus assaying,
and genotypes determined by PCR-RFLP methodology. The results showed no alteration in the risk of BC and DNA
damage brought about by either XRCC1 (Arg399Gln) or XRCC3 (Thr241Met) action in either of the two groups. Nev-
ertheless, on evaluating BC risk in women presenting levels of chromosome damage above the mean, the XRCC3
Thr241Met polymorphism was found to be more frequent in the BC group than in the control, thereby leading to the
conclusion that there is a slight association between XRCC3 (241 C/T) genotypes and BC risk in the subgroups with
higher levels of chromosome damage.
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Breast cancer (BC) is one of the most common causes
of death among women, with every indication of a slow and
steady decrease in the age of onset. The risk factors for BC
include the early age of menarche, delayed menopause, the
use of contraceptives, hormonal replacement therapy, the
above average body-mass index, exposure to environmen-
tal pollutants, smoking and alcohol use (Kristensen and
Borresen-Dale, 2000; Hulka and Moorman, 2001; Kang et
al., 2002). However, it is generally believed that the initia-
tion of BC is a consequence of cumulative genetic damage
thereby leading to genetic alterations, with subsequent acti-
vation of proto-oncogenes and inactivation of tumor-sup-
pressor genes (Mitrunen and Hirvonen, 2003). A large
number of genetic variants associated with BC risk have
been identified in genes involved in a wide variety of func-
tions, including steroid hormone metabolism, detoxifica-
tion of environmental carcinogens, tumor suppression and
DNA damage repair (Dunning et al., 1999).
Polymorphisms in DNA repair genes are common.
Studies have revealed that the effects of these polymor-
phisms on DNA repair ability contribute to individual dif-
ferences (Pachkowski et al., 2006). There are two impor-
tant genes involved in this process. One, the X-Ray Repair
Cross Complementing 1 (XRCC1) gene involved in the
Base Excision Repair (BER) pathway, is linked with a scaf-
folding protein that directly associates with other proteins,
such as DNA polymerase ß , PARP (ADP-ribose polymer-
ase) and DNA ligase III, in a complex that facilitates pro-
cesses of BER DNA repair (Caldecott et al., 2003). The
other, XRCC3, one of the key components of the homolo-
gous repair (HR) pathway, functions in the cross-link repair
of DNA double-strand breaks (DSBs) by interacting and
stabilizing Rad51 (Schild et al., 2000; Thompson and
Schild, 2002).
It is common knowledge that chromosome damage
results from non- or misrepaired DSBs, with many poly-
Genetics and Molecular Biology, 33, 4, 637-640 (2010)
Copyright © 2010, Sociedade Brasileira de Genética. Printed in Brazil
www.sbg.org.br
Send correspondence to Raquel Alves dos Santos. Faculdade de
Medicina de Ribeirão Preto, Departamento de Genética, Bloco G,
Av. Bandeirantes 3900, 14049-900 Ribeirão Preto, SP, Brazil.
E-mail: rasantos@rge.fmrp.usp.br.
Short Communication
morphisms, such as those of DNA repair genes, having
been associated with increased cancer risk, and a possibly
even higher level of chromosome damage (Norppa 2004).
Thus, the aim hereby was to investigate the relationship
between XRCC1 (Arg399Gln) and XRCC3 (Thr241Met)
SNPs and chromosomal damage in untreated BC women
and healthy controls.
Blood samples for genotyping and micronucleus as-
saying were obtained from 65 untreated women, with ages
ranging from 25 to 60 (mean age 50.6), diagnosed with in
situ or invasive ductal breast carcinoma and free from any
pathological manifestation associated with the use of medi-
cation and possibly leading to DNA damage. Of the 65
women in the patient group 33 (50.7%) were post- and 32
(49.3%) pre-menopausal. The control group consisted of
85 women, ages ranging from 25 to 60 (mean age 48.7)
with 42 (49.4%) post- and 43 (50.6%) premenopausal.
Each was enrolled in the study after detailed investigation,
thereby ensuring the absence from any form of breast pa-
thology. These were matched to patients according to the
following variables: all the volunteers came from the same
geographical location, with identical dietary habits, and
without prior occupational exposure to genotoxic chemi-
cals. None reported alcohol consumption, genotoxic medi-
cine intake, the presence of known inherited genetic disor-
ders or chronic diseases, or the exposure to ionizing or
non-ionizing radiation, even for diagnostic or therapeutic
purposes, for at least one month previously. The investiga-
tion received prior approval by the National Ethics Com-
mittee (CONEP: 1217/2004), and was undertaken in accor-
dance with defined ethical standards. Informed consent was
obtained from patients and controls before inclusion in the
study and sample collection.
Genomic DNA samples were obtained from blood
lymphocytes for genotyping by using a Wizard® Genomic
DNA Purification Kit (Promega, Madison, WI). G399A
polymorphism of the XRCC1 gene was determined by
PCR-RFLP with the following primers: sense,
5’-TCTCCCTTGGTCTCCAACCT-3’ and antisense,
5’-AGTAGTCTGCTGGCTCTGG-3’. The 402 bp product
was digested overnight with 5 U of the restriction enzyme
MspI. The G allele was digested into 269 and 133 bp frag-
ments. Nevertheless, when the A allele was present, the
402 bp fragment remained intact. C241T polymorphism of
the XRCC3 gene was genotyped with the following prim-
ers: sense, 5’-GGTCGAGTGACAGTCCAAAC-3’ and
antisense, 5’-TGCAACGGCTGAGGGTCTT-3’. The
455 bp product was digested overnight with 5 U of the re-
striction enzyme NlaIII. The Leu allele was digested into
210, 140 and 105 bp fragments.
In order to stimulate cell proliferation, lymphocyte
cultures were prepared for micronucleus assaying by com-
bining 0.5 mL of isolated lymphocytes in plasma with 5 mL
of a complete medium containing 78% of RPMI (Sig-
ma-Aldrich Co., USA), 20% inactivated fetal bovine serum
(Gibco-Invitrogen, Denmark), and both of the antibiotics
penicillin (5 g/mL, Sigma-Aldrich Co., USA) and strepto-
mycin (10 g/mL, Sigma-Aldrich Co., USA), as well as 2%
phytohemagglutinin (Life Technologies, Grand Island,
NY, USA). Cultures were incubated at 37 °C. According to
the Fenech and Morley (1985) method, after 44 h of incuba-
tion, cytochalasin B (Sigma-Aldrich Co., USA) was added
to the cultures to a final concentration of 4 g/mL. The cul-
tures were stopped after 72 h, whereat the cells were har-
vested by centrifugation, submitted to cold hypotonic
treatment (1% of sodium citrate), and fixed in two changes
of methanol-acetic acid (3:1). The fixed cells were spread
onto pre-cleaned glass slides, air-dried, and then stained
with a Giemsa solution (Sörensen Buffer, pH 6.8) for 7 min.
1000 binucleated cells were analyzed, whereupon micro-
nucleus frequency (MNF), micronucleated cell frequency
(MCF) and the nuclear division index (NDI) were deter-
mined for each cell according to criteria described by Fe-
nech (2000).
The Mann-Whitney statistical test was applied for
comparing MNF between patients and controls. The level
of DNA damage in different genotypes was analyzed with
one-way ANOVA, whereas statistical differences between
groups for BC risk was calculated using Fisher’s exact test
(two-tailed). On considering that high chromosome dam-
age could possibly be associated with inefficient DNA re-
pair, subjects with MN frequencies higher than the mean
for the respective group, were selected for further analysis,
as recommended by Synowiec et al. (2008). Crude odds ra-
tios (ORs) were calculated and obtained with 95% confi-
dence intervals (CIs). Results were considered significant
when p < 0.05.
The polymorphic variants of the two DNA repair
genes, XRCC1 (399G/A) and XRCC3 (241 C/T), and geno-
type distribution of the BC and control groups, were in
agreement with those predicted by Hardy-Weinberg equi-
librium. There was no difference between patients and con-
trols, as regards XRCC1 and XRCC3 genotype frequencies
(Table 1). Although it has been suggested that XRCC1 and
XRCC3 polymorphisms are involved in BC risk, we did not
find such correlation, mainly due to the small sample size.
Nevertheless, it has been revealed that subtle defects in
DNA repair capacity, arising from low-penetrance genes or
their combinations, are modified by other genetically deter-
mined or environmental risk factors and are correlated with
BC risk (Synowiec et al., 2008).
We are aware that this is not an epidemiological
study. Rather, our primary objective was to evaluate the
correlation between genotype (variants of DNA repair
genes) and phenotype (spontaneous chromosome damage).
The results obtained after genotype analysis and chromo-
some damage expressed by MNF are presented in Table 1.
In both patient and control groups, no genetic variant of
XRCC1 or XRCC3 influenced the frequency of micronuclei
detected in peripheral lymphocytes. We have previously re-
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ported that untreated Brazilian BC patients displayed
higher levels of chromosome damage than healthy controls
(Santos et al., 2010). Furthermore, it has been suggested
that genome damage in lymphocytes may be correlated
with cancer-initiating events in target tissues, via a com-
mon genetic, dietary or environmental factor (Bonassi et
al., 2007). Hence, genetic polymorphisms might explain
part of the association between chromosome damage levels
and cancer risk (Norppa, 2004). However, in a pooled anal-
ysis, Mateuca et al. (2008) suggested that single DNA re-
pair gene polymorphisms are not likely to have a major
impact on MN frequencies, whereas combinations of dif-
ferent DNA repair genes, and the interplay between
hOGG1326, XRCC1399, XRCC3241, genotypes and environ-
mental factors are more likely to modulate MN levels.
Table 2 shows the distribution of XRCC1 (399G/A)
and XRCC3 (241 C/T) genotypes in groups of patients and
controls with higher than mean level of spontaneous DNA
damage in both (19.3 for patients and 10.4 for controls). On
considering XRCC1 gene variants, no correlation between
the frequencies of genotypes and MN was found. On the
other hand, XRCC3 polymorphism was only slightly asso-
ciated with BC risk in those individuals that presented
higher levels of chromosome damage. This was interesting,
especially when considering that susceptibility and risk
biomarkers contribute to identifying high-risk subgroups of
the population, independent of their association with expo-
sure or involvement in a defined pathway or mechanism
(Boffeta, 2009). Notwithstanding, such a correlation can-
not be emphasized, especially on considering that when
lymphocytes of BC patients and healthy controls were chal-
lenged to repair the in vitro etoposide-induced DNA dam-
age, the response was similar in both groups, as previously
demonstrated (Teixeira et al., 2009). Moreover, the mani-
festation of the effects of DNA repair enzyme polymor-
phisms may be quite different between breast tissue
undergoing continual exposure to the effects of hormones
and lymphocytes.
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Table 1 - The genotype frequencies of XRCC1 and XRCC3 gene variants, and levels of chromosome damage as evaluated by micronucleus (MN) assay in
untreated breast cancer patients and controls.
Genotype Breast cancer patients
(n = 65)
Controls
(n = 85)
OR
(95% CI)
Breast cancer patients
MNF (‰) M  SD
Controls MNF (‰)
M  SD
N Frequency N Frequency
XRCC1
Arg/Arg 24 0.37 24 0.28 1.0 (reference) 16.9  10 10.1  5.8
Arg/Gln 39 0.60 53 0.62 0.73 (0.3-1.4) 20.1  11.1 8.9  6.5
Gln/Gln 2 0.03 8 0.10 0.25 (0.04-1.3) 33  5.6 10.8  5.3
Arg/Gln+Gln/Gln 41 0.63 61 0.72 0.6 (0.3-1.3) 20.7  10.8 9.3  6.2
p = 0.2 p = 0.7
XRCC3
Thr/Thr 28 0.43 49 0.58 1.0 (reference) 18.7  8.9 11.2  6.3
Thr/Met 31 0.48 29 0.34 1.8 (0.9-3.7) 19.7  12.2 8.3  5.3
Met/Met 6 0.09 7 0.08 1.5 (0.4-4.9) 20.3  12.2 10.8  7.8
Thr/Met+Met/Met 37 0.57 36 0.42 1.7 (0.9-3.4) 19.8  12.1 9.3  6
p = 0.9 p = 0.3
MNF: micronucleus frequency; OR: odds ratio; M: mean; SD: standard deviation.
Table 2 - DNA repair-gene polymorphisms in breast cancer patients and controls with high levels of chromosome damage.
Genotype Breast cancer patients (n = 32) Controls (n = 21) OR (95% CI)
Number Frequency Number Frequency
XRCC1
Arg/Arg 9 0.28 4 0.19 1.0 (reference)
Arg/Gln+Gln/Gln 23 0.72 17 0.81 1.6 (0.4-6.3)
XRCC3
Thr/Thr 12 0.37 15 0.71 1.0 (reference)
Thr/Met+Met/Met 20 0.63 6 0.29 4.1 (1.2-13.6)
OR: odds ratio.
In conclusion, the levels of chromosome damage ob-
served in breast cancer patients and healthy controls were
not associated to the XRCC1 (399G/A) and XRCC3 (241
C/T) genotypes. Nevertheless there actually was a weak as-
sociation between several other XRCC3 genotypes and BC
risk in the subgroup where this damage was higher. Such an
association must be interpreted with caution, when consid-
ering that the odds ratios obtained, even though pertaining
to low-penetrance genes, were statistically significant.
Thus, only the common expression of a considerable num-
ber of such genes could possibly change this statistical sig-
nificance into a biological or medical one.
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